Skip Navigation


Studies




Email This Page Print This Page Change Font Size
Print This Page for Your Doctor


New Search


1 through 3 of 3            Reset Filters 
Sort By:                       Trial Title    |    Age Range    |    Last Updated  
Title begins with...   A B C D E F G H I J K L M N O P Q R S T U V W X Y Z    

 
A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone (D8480C00055)
  • Keyword(s): Cancer, Tumour, Advanced Solid Tumour, GBM, Glioblastoma




  • Location:
    • Phoenix, Arizona


  • Status:
    • Active but closed to enrollment
    • Last Updated Thursday, August 13, 2009


  • Age Range
    • 18 and older


  • Summary
    • The purpose of this study is to see how effective cediranib is in treating a brain tumour called recurrent glioblastoma. Two drugs are being tested in this study. Lomustine is an approved oral chemotherapy that belongs to the class of drugs called alkylating agents. Cediranib is a new drug that has not yet been approved for this disease. This study will compare the use of lomustine with cediranib, cediranib alone or lomustine with placebo ("inactive substance") to see whether the combination or cediranib alone will be more effective than the chemotherapy alone (lomustine) in preventing the growth of cancer cells.


  • Primary Sponsor
    • AstraZeneca


  • More Information


 
Read more!
Childhood Brain Cancer Causes Other Long-Term Problems  11/2/2009 12:00:00 AM (MST)


Treatment leaves survivors with significant cognitive decline, researchers find
 
Cilengitide in Subjects With Newly Diagnosed Glioblastoma Multiforme and Unmethylated MGMT Gene Promoter - a Multicenter, Open-label Phase II Study, Investigating Two Cilengitide Regimens in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy). (EMD 121974-012)
  • Keyword(s): Newly diagnosed Glioblastoma multiforme (GBM) (WHO Grade IV)




  • Location:
    • Phoenix, Arizona


  • Status:
    • Open and enrolling subjects
    • Last Updated Monday, February 08, 2010


  • Age Range
    • 18 and older


  • Summary
    • CORE is a Phase II clinical trial in newly diagnosed glioblastoma multiforme (GBM) in patients with an unmethylated promoter of the methylguanine-DNA methyltransferase (MGMT) gene in the tumor tissue. The MGMT gene promoter is a section of DNA that acts as a controlling element for a specific NDA product (MGMT). Methylation of the MGMT gene promoter has been found to appear to be a predictive marker for benefit from temozolomide (TMZ) treatment. In a safety run-in period in dedicated study centers the safety and tolerability of Cilengitide given as an intense treatment in combination with the first part of standard therapy will be assessed. Thereafter the trial will investigate the overall survival and progression-free survival in patients receiving two different regimens of Cilengitide in combination with standard treatment versus standard treatment alone.


  • Primary Sponsor
    • EMD Serono


  • More Information


 
Read more!
Childhood Brain Tumors May Respond to Measles Virus  6/2/2010 12:00:00 AM (CST)


Treatment looks promising in laboratory and animal tests, researchers say
 
Open-label, Dose Confirmation Study of Interstitial 131I-chTNT-1/B MAb (Cotara®) for the Treatment of Glioblastoma Multiforme (GBM) at First Relapse (PPHM 0503)
  • Keyword(s): glioblastoma multiforme, GBM brain cancer, Cotara, radioactive isotope, monoclonal antibody, Glioblastoma multiforme at first relapse




  • Location:
    • Phoenix, Arizona


  • Status:
    • Open and enrolling subjects
    • Last Updated Monday, February 08, 2010


  • Age Range
    • 18 and older


  • Summary
    • Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody. This monoclonal antibody is designed to bind tumor cells and deliver radiation directly to the center of the tumor mass while minimizing effects on normal tissues. Cotara® thus literally destroys the tumor "from the inside out". This may be an effective treatment for glioblastoma multiforme, a malignant type of brain cancer.


  • Primary Sponsor
    • Peregrine Pharmaceuticals


  • More Information


 
Read more!
Exercise in Adolescence May Cut Risk of Deadly Brain Tumor  10/6/2009 12:00:00 AM (CST)


Physical activity later in life didn't seem to matter, study finds
Epilepsy

Epilepsy

We are seeking individuals with epilepsy to participate in research studies at St. Joseph's.

Learn more...


Brain Tumors

Brain Tumors

We are seeking individuals with Brain Tumors to participate in research studies at St. Joseph's.

Learn more...

Browse Trials by Area

We have also organized the clinical trial by area. Hover over the highlighted areas on the map to locate trials in your area.

Click the highlighted areas to find trials

Browse Trials by Conditions

We have also organized the clinical trial by Health Conditions. Choose a condition from the drop-down menu to start your search.

Bottom of Navigation